'Strikeout Ovarian Cancer' Game Set For April 12

by Clyde Verdin
Register Online +0
'Strikeout Ovarian Cancer' Game Set For April 12

BATON ROUGE, La. – On Saturday, April 12, the LSU softball team will host the third-annual “Strikeout Ovarian Cancer” game at 6 p.m. at Tiger Park, as the Tigers will host the University of Georgia Bulldogs for game two of the Southeastern Conference series that weekend.

Prior to the start of the contest, there will be a pregame ceremony honoring the survivors and those lost to ovarian and other GYN cancers down on the field before lineups are introduced. Interested parties that would like to be included in the pregame festivities are asked to contact Assistant Marketing Director Jennifer Chow at jchow@lsu.edu, or by filling out the online form by Thursday, April 10.

LSU will wear commemorative teal jerseys to celebrate the survivors and spread awareness of ovarian cancer, along with teal batting helmets and display teal banners throughout the park. Fans in attendance are asked to come to the game wearing teal as well.

“It is such a cool game because you have the survivors or the family members who have lost loved ones to cancer come out, and it’s a chance for us to honor these women that don’t have a place to be honored,” head softball coach Beth Torina said. “Not only are we making people aware, but we’re able to honor these really strong and wonderful women on the field before the game.”

That same morning will be the second-annual “Geaux Teal Ovarian Cancer Walk” that will begin at Tiger Park. The two-mile walk that featured over 200 participants last year and runs through the LSU campus will help to continue to spread awareness of ovarian cancer in the Baton Rouge community, in relationship with Coach Torina’s mother Betty, who was diagnosed in November of 2010 and is a survivor of the disease.

“The inaugural Geaux Teal Walk was such a success last year, and because of it we were able to help so many women in the Baton Rouge community that are survivors of this cancer, or those who are continuing to receive treatment for this disease,” Torina said. “We hope to do even more with the second one this year, as it continues to grow so we can continue to raise awareness and help as many people as we can.”

For anyone interested in supporting the walk, online registration is available here. All monies generated from the event will stay in the Baton Rouge area for the continuing care and treatment of women with ovarian cancer. For more information on volunteering or the organization itself, contact geauxteal@gmail.com.

You can connect with Geaux Teal and find out more about the event through the organization’s social media pages at https://www.facebook.com/geauxteal and https://twitter.com/geauxteal.

About Geaux Teal
Geaux Teal’s mission is to raise awareness for women of all ages about the signs and symptoms of ovarian cancer. The continual increase in education and overall awareness of ovarian cancer is the primary founding principle of Geaux Teal. Through this emphasis on educational and awareness objectives we hope to accomplish an early detection screening test, further understandings of the prognosis of ovarian cancer, improve doctor/patient relationships and shared knowledge as well as increased medical education. Ultimately, one day we will equate longer survivorship with women’s understanding of ovarian cancer and its dangers. Geaux Teal will promote community based events that raise awareness, increased education and research funds for ovarian cancer.

About Ovarian Cancer
Ovarian cancer is the 9th most common cancer among women, excluding non-melanoma skin cancers. It ranks 5th in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Ovarian cancer accounts for about 3% of all cancers in women. A woman’s risk of getting ovarian cancer during her lifetime is about 1 in 71. Her lifetime chance of dying from ovarian cancer is about 1 in 95. Only 20% of patients are diagnosed in early stage. When ovarian cancer is found early at a localized stage and treated properly, about 94% of patients live longer than 5 years after diagnosis. Unfortunately, most women are diagnosed in more advanced stages in which the cure rate dramatically drops. The recurrence rate for these advanced stages is 70 percent.